Novartis AG (NYSE: NVS) Stock Competitors & Peer Comparison
See NVS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NVS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $153.81 | -0.54% | 292.3B | 17.70 | $8.69 | +3.09% |
| LLY | $1,172.86 | -0.28% | 1.1T | 37.28 | $31.49 | +0.57% |
| JNJ | $268.04 | -0.73% | 640.5B | 24.77 | $10.73 | +1.98% |
| ABBV | $255.48 | -1.03% | 451.4B | 25.07 | $10.19 | +2.67% |
| MRK | $148.35 | -0.80% | 366.3B | 46.20 | $3.21 | +2.27% |
| AZN | $162.70 | -1.11% | 252.3B | 17.57 | $9.26 | +1.29% |
| AMGN | $432.42 | -1.05% | 233.4B | 19.33 | $22.37 | +2.30% |
| NVO | $45.61 | -1.41% | 202.5B | 11.34 | $4.02 | +2.56% |
| GILD | $145.68 | -2.14% | 180.9B | -373.54 | -$0.39 | +2.22% |
| PFE | $27.96 | -0.21% | 159.4B | 9.17 | $3.05 | +6.17% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
NVS vs LLY Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while LLY trades at $1,172.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas LLY's P/E ratio is 37.28. In terms of profitability, NVS's ROE is +0.30%, compared to LLY's ROE of +0.93%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for NVS.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
NVS vs JNJ Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, JNJ has a market cap of 640.5B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while JNJ trades at $268.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas JNJ's P/E ratio is 24.77. In terms of profitability, NVS's ROE is +0.30%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for NVS.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
NVS vs ABBV Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, ABBV has a market cap of 451.4B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while ABBV trades at $255.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas ABBV's P/E ratio is 25.07. In terms of profitability, NVS's ROE is +0.30%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for NVS.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
NVS vs MRK Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, MRK has a market cap of 366.3B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while MRK trades at $148.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas MRK's P/E ratio is 46.20. In terms of profitability, NVS's ROE is +0.30%, compared to MRK's ROE of +0.07%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MRK's competition here
AstraZeneca PLC (NYSE: AZN)
NVS vs AZN Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, AZN has a market cap of 252.3B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while AZN trades at $162.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas AZN's P/E ratio is 17.57. In terms of profitability, NVS's ROE is +0.30%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
NVS vs AMGN Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, AMGN has a market cap of 233.4B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while AMGN trades at $432.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas AMGN's P/E ratio is 19.33. In terms of profitability, NVS's ROE is +0.30%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
NVS vs NVO Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, NVO has a market cap of 202.5B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while NVO trades at $45.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas NVO's P/E ratio is 11.34. In terms of profitability, NVS's ROE is +0.30%, compared to NVO's ROE of +0.59%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for NVS.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
NVS vs GILD Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, GILD has a market cap of 180.9B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while GILD trades at $145.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas GILD's P/E ratio is -373.54. In terms of profitability, NVS's ROE is +0.30%, compared to GILD's ROE of -0.16%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
NVS vs PFE Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, PFE has a market cap of 159.4B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while PFE trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas PFE's P/E ratio is 9.17. In terms of profitability, NVS's ROE is +0.30%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVS is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for NVS.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
NVS vs BMY Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, BMY has a market cap of 136B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while BMY trades at $66.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas BMY's P/E ratio is 11.23. In terms of profitability, NVS's ROE is +0.30%, compared to BMY's ROE of +0.47%. Regarding short-term risk, NVS is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for NVS.Check BMY's competition here
Sanofi (NASDAQ: SNY)
NVS vs SNY Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, SNY has a market cap of 107.6B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while SNY trades at $44.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas SNY's P/E ratio is 9.76. In terms of profitability, NVS's ROE is +0.30%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVS is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVS.Check SNY's competition here
GSK plc (NYSE: GSK)
NVS vs GSK Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while GSK trades at $50.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas GSK's P/E ratio is 10.98. In terms of profitability, NVS's ROE is +0.30%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
NVS vs BIIB Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, BIIB has a market cap of 32.3B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while BIIB trades at $218.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas BIIB's P/E ratio is 13.79. In terms of profitability, NVS's ROE is +0.30%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
NVS vs HZNP Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVS.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
NVS vs GRFS Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, GRFS has a market cap of 6.5B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while GRFS trades at $7.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas GRFS's P/E ratio is 8.83. In terms of profitability, NVS's ROE is +0.30%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
NVS vs OGN Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while OGN trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas OGN's P/E ratio is 4.11. In terms of profitability, NVS's ROE is +0.30%, compared to OGN's ROE of +0.23%. Regarding short-term risk, NVS is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVS.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
NVS vs AMRN Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, AMRN has a market cap of 288.9M. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while AMRN trades at $13.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas AMRN's P/E ratio is -139.70. In terms of profitability, NVS's ROE is +0.30%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, NVS is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
NVS vs SCLX Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, SCLX has a market cap of 46.1M. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while SCLX trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas SCLX's P/E ratio is -0.14. In terms of profitability, NVS's ROE is +0.30%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
NVS vs SCLXW Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, SCLXW has a market cap of 42.1M. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.30%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
NVS vs MIRA Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, MIRA has a market cap of 31.5M. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while MIRA trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas MIRA's P/E ratio is -0.52. In terms of profitability, NVS's ROE is +0.30%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
NVS vs BDSIW Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVS's ROE is +0.30%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVS is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
NVS vs CRXT Comparison August 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 292.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $153.81 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.70, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVS.Check CRXT's competition here